Patricia Davidson, MD
Cardiovascular Disease · Washington, DCNPI 1497829196
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 53.6% of the total. Reporting peaked in 2019 at $4,690 and has fallen 78.9% since, to $990 in 2025.
Across 182 payments — averaging $59.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Boston Scientific$1K
- Novo Nordisk$1K
- Pfizer$642
- Amgen$623
- Novartis$340
- plus $1K from 14 others
Across 5 payments — averaging $8770.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$44K
What the payments were for
- Travel & lodging$5,47050%
- Food & beverage$5,31949%
- Education$1171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 37 | $5,843 |
| Boston Scientific | 14 | $1,179 |
| Novo Nordisk | 22 | $1,030 |
| Pfizer | 26 | $642 |
| Amgen | 19 | $623 |
| Novartis | 20 | $340 |
| Johnson & Johnson | 8 | $273 |
| AstraZeneca | 8 | $204 |
| Esperion Therapeutics, Inc. | 2 | $139 |
| Bridgebio Pharma, Inc. | 1 | $117 |
| Merck | 6 | $114 |
| Kowa Pharmaceuticals America, Inc. | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $55 |
| Atricure, Inc. | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Lilly USA, LLC | 2 | $45 |
| Bayer | 1 | $31 |
| AbbVie | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allure CRT Pacemaker$3,419
- Ensite Cardiac Mapping System$1,515
- WATCHMAN Access System$834
- Ozempic$353
- Repatha$256
- Wegovy$242
- AVEIR$157
- Assurity Pacemaker$130
- NEXLIZET$120
- NEXLETOL$120
- Attruby$117
- VYNDAQEL$116
How this compares
$10,905 in reported general payments places this provider in the 80th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $121,828 |
| JardianceEmpagliflozin | 108 | $101,366 |
| OzempicSemaglutide | 65 | $88,424 |
| FarxigaDapagliflozin Propanediol | 60 | $41,625 |
| JanuviaSitagliptin Phosphate | 52 | $39,697 |
| Ezetimibe | 310 | $13,267 |
| EntrestoSacubitril/Valsartan | 13 | $8,569 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 128 | $7,550 |
| Candesartan Cilexetil | 69 | $5,108 |
| Rosuvastatin Calcium | 278 | $4,693 |
| Cyclosporine | 12 | $4,413 |
| Metoprolol Succinate | 261 | $4,328 |
| Fluvastatin ErFluvastatin Sodium | 15 | $4,205 |
| Olmesartan Medoxomil | 151 | $3,452 |
| Ranolazine ErRanolazine | 15 | $3,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $642 | $121,82893 claims |
| Novo NordiskOzempic | $1,030 | $88,42465 claims |
| AstraZenecaFarxiga | $204 | $41,62560 claims |
| MerckJanuvia, Janumet Xr | $114 | $41,60963 claims |
| NovartisEntresto | $340 | $8,56913 claims |
| AbbVieSynthroid | $26 | $1,03418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Felton AndersonWashington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.